0 -5 0 helicase, mutated in Bloom syndrome, which plays an important role in response to DNA double-strand breaks and stalled replication forks. Here, we show that BCR/ABL tyrosine kinase, which also modulates DNA repair capacity, is associated with elevated expression of BLM. Downregulation of BLM by antisense cDNA or dominantnegative mutant inhibits homologous recombination repair (HRR) and increases sensitivity to cisplatin in BCR/ABLpositive cells. Bone marrow cells from mice heterozygous for BLM mutation, BLM Cin/ þ , transfected with BCR/ ABL display increased sensitivity to cisplatin compared to those obtained from the wild-type littermates. BCR/ABL promotes interactions of BLM with RAD51, while simultaneous overexpression of BLM and RAD51 in normal cells increases drug resistance. These data suggest that BLM collaborates with RAD51 to facilitate HRR and promotes the resistance of BCR/ABL-positive leukemia cells to DNA-damaging agents.
Introduction
BCR/ABL oncogenic tyrosine kinase is present in most chronic myelogenous leukemia (CML) patients and in a cohort of acute lymphocytic leukemia patients (Epner and Koeffler, 1990) . BCR/ABL allows cells to survive and proliferate in the absence of growth factors, and promotes invasion and metastasis (Arlinghaus and Sun, 2004) . Another role of BCR/ABL in hematological malignancies, only recently recognized, is its modulation of responses to DNA damage leading to drug resistance and genomic instability (Skorski, 2002) . Cells expressing BCR/ABL kinase are protected from genotoxic stress (Skorski, 2002) . The degree of resistance depends on BCR/ABL expression level/kinase activity (Cambier et al., 1998; Issaad et al., 2000; Keeshan et al., 2001) . Since BCR/ABL expression and kinase activity decreases with cell differentiation (Maxwell et al., 1987; Lindner et al., 2003) , less differentiated and more aggressive leukemia cells may have better chances to survive genotoxic stress. Moreover, BCR/ABL leukemia cells can receive additional signals from extracellular matrix components, for example, fibronectin providing additional protection from apoptosis induced by genotoxic stress (van der Kuip et al., 2001) . It is also expected that some BCR/ABL-positive imatinib mesylate-resistant cells may display significant drug resistance because of the elevated levels/enhanced kinase activity of BCR/ ABL (Gorre et al., 2001; Yamamoto et al., 2004) .
Although the level of DNA damage in BCR/ABLtransformed cells is similar or even higher than in nontransformed counterparts, the former cells can repair the lesions more efficiently Hoser et al., 2003; Laurent et al., 2003; Dierov et al., 2004) . Our previous studies have shown that the BCR/ABL-STAT5-RAD51 pathway stimulates homologous recombination repair (HRR), which contributes to the resistance of leukemia cells to druginduced DNA damage (Slupianek et al., 2001) . These findings were supported by the observation that BCR/ ABL-related fusion tyrosine kinases (FTKs) such as TEL/ABL, TEL/JAK2, TEL/PDGFbR, NPM/ALK and ZNF198/FGFR1 also induce STAT5 to enhance the expression of RAD51 Heath and Cross, 2004) . RAD51 and its bacterial homologue RecA play a central role in the response to DNA damage by catalyzing HRR (West, 2003) . Elevated levels of RAD51 proteins are present in many tumors (Raderschall et al., 2002) and, in general, are positively correlated with resistance to genotoxic treatment (Vispe et al., 1998; Collis et al., 2001) .
DNA unwinding is necessary for the initiation of HRR (eg generation of a single-stranded (ss) DNA branch) and resolution of the HRR intermediates (eg Holliday junctions ¼ HJs). DNA helicases play a vital role in DNA unwinding (Lohman and Bjornson, 1996) . The RecQ-like helicase family consists of five known proteins: Bloom protein (BLM), WRN, RTS, RecQL1 and RecQL5, which display redundant and unique biological activities. RecQ helicases may act early in the recombination pathway by creating a singlestranded substrate that can be used by RecA (RAD51) to initiate homologous pairing (Harmon and Kowalczykowski, 1998) and/or at the late stages by catalyzing branch migration of HJs generated during HRR (Constantinou et al., 2000; Karow et al., 2000) . Studies in Sacharomyces cerevisiae clearly show that the recombination intermediates, if not resolved, may be toxic for cells (Fabre et al., 2002) . Cell lethality may be alleviated by the activity of SGS1 helicase (orthologue of BLM and WRN) (Gangloff et al., 2000) , through promoting procession of recombination structures (Kaytor et al., 1995; Schild, 1995) . In accordance, loss of function of RecQ-like helicases may lead to increased sensitivity to DNA-damaging agents (Imamura et al., 2001 ).
An aberrant regulation of RecQ-like helicases (including sharp upregulation of BLM) has been found in tumors (Kawabe et al., 2000; Turley et al., 2001) . Here, we report that expression of the BLM RecQ-like helicase is stimulated by BCR/ABL and other FTKs. BLM may play an important role in response to cisplatin treatment in BCR/ABL-positive leukemia cells most likely through the interactions with RAD51 during HRR.
Results

BCR/ABL stimulates BLM expression and helicase activity
Using the database described before , we observed that expression of the human RecQlike helicases, BLM, WRN, RTS and RecQL1, were upregulated, and that the expression of RecQL5 was downregulated in freshly obtained leukemia cells in comparison to normal cells (Figure 1a ). BCR/ABLmediated increase of the expression of BLM was confirmed by Northern analysis of total RNA prepared from murine hematopoietic cell line 32D and clones expressing BCR/ABL cultured for 12 h in the absence of IL-3 (Figure 1b ). Under this condition, about 65, 10, 18 and 7% of parental cells and 42, 39, 17 and 2% of 32D-BCR/ABL cells were in G0/G1, S, G2/M and sub-G0/ G1 cell cycle phases. As expected, BLM protein was primarily localized in the nucleus and its expression was stimulated by BCR/ABL (Figure 1c) . Furthermore, Western analysis of various murine and human cell lines and primary CML cells confirmed that BCR/ABL kinase stimulates the expression of BLM helicase in the absence of growth factors (Figure 1d ). Abrogation of BCR/ABL kinase activity by STI571 (data not shown) caused downregulation of BLM in 32D-BCR/ABL cells ( Figure 1d ) and inhibition of cell cycle (62, 8, 18 and 12% of cells were in G0/G1, S, G2/M and sub-G0/G1 cell cycle phases, respectively). The addition of IL-3 to STI571-treated 32D-BCR/ABL cells rescued cell cycle progression (49, 33, 15 and 3% of cells were in G0/G1, S, G2/M and sub-G0/G1 cell cycle phases, respectively) and BLM protein expression (Figure 1d) .
BLM protein contains a caspase-3 cleavage site (Bischof et al., 2001; Freire et al., 2001 ) and was cleaved presumably by caspase-3-dependent mechanism in MO7 cells incubated in the absence of GM-CSF; this effect could be prevented by Z-VAD-FMK (Figure 1e ). However, BLM was protected from caspase-3-mediated cleavage in BCR/ABL-transformed MO7 cells (Figure 1e) .
Interestingly, other members of the BCR/ABL-related family of FTKs such as TEL/ABL, TEL/JAK2, TEL/ PDGFbR and NPM/ALK were also associated with stimulation of BLM protein expression in BaF3 murine hematopoietic cells in the absence of IL-3 (Figure 1f We also used an inducible HRR model (Pierce et al., 1999) to examine the role of BLM in BCR/ABL cells. As shown previously (Slupianek et al., 2001) , BCR/ABL induced HRR of double-strand breaks (DSBs) in the DR-GFP gene. This is reflected by restoration of GFP protein expression and measured by scoring of GFPpositive cells. Downregulation of BLM in BCR/ABLpositive cells, but not in normal counterparts, by transfection with BLM antisense (AS) cDNA was associated with decreases in DSB repair, presumably through inhibition of homologous recombination-associated DNA repair ( Figure 2b ). (Figure 3b ). In addition, BLM Cin/ þ cells transfected with BCR/ ABL displayed higher sensitivity to cisplatin than the wild-type þ / þ counterparts (Figure 3c ). GFP-positive BLM Cin/ þ and wild-type cell populations expressed similar levels of BCR/ABL (data not shown). Expression of BLM protein is reduced by B50% in the former animals in comparison to the latter ones (Goss et al., 2002) . In conclusion, BLM appears to modulate the sensitivity of BCR/ABL cells to the genotoxic treatment, as when BLM levels decrease, sensitivity to cisplatin increases.
To explore this effect, BLM was ectopically expressed in 32D parental cells, and mixture of cell clones were used for the experiments. Overexpression of BLM (Figure 4b , 32D-BLM group) was not associated with drug resistance in comparison to control cells (Figure 4b , 32D-E group) when cultured in the presence of IL-3 (Figure 4a ). This observation is in accordance with another report (Beamish et al., 2002) . RAD51, also upregulated by BCR/ABL and a known protein partner of BLM, plays an important role in resistance to DNA damage (Slupianek et al., 2001) . As expected, elevated levels of RAD51 in parental cells (Figure 4b , 32D-RAD51) induced modest drug resistance (Figure 4a) . Interestingly, simultaneous overexpression of BLM and RAD51 (Figure 4b , 32D-BLM þ RAD51 group) synergistically increases the drug-resistant phenotype as compared to that of RAD51 or BLM alone (Figure 4a , 32D-RAD51 and 32D-BLM group, respectively). These data suggest that BLM may be a cofactor in the response of cells expressing BCR/ABL to DNA damage.
Enhanced interactions of BLM with RAD51 in BCR/ ABL-positive cells
Using GST-BLM(aa 1-212) or GST-RAD51 fusion proteins as bait, we identified more BLM-RAD51 complexes in BCR/ABL cells in comparison to parental cells 12 h after cisplatin treatment in the absence of IL-3 (Figure 5a and b) . In addition, more BLM and RAD51 were present in anti-RAD51 and anti-BLM immunoprecipitates, respectively, obtained from cisplatin-treated BCR/ABL cell lysates than from parental cell lysates (Figure 5c and d) . Immunofluorescence studies demonstrated enhanced, but partial colocalization of BLM and RAD51 in BCR/ABL cells in comparison to parental cells (Figure 5e and f). The percentage of BLM and RAD51 involved in the foci colocalization in BCR/ABL cells increased B5 times after the treatment with cisplatin (P ¼ 0.004); in comparison, individual BLM and RAD51 foci grew B2 and B1.5 times.
Discussion
We reported previously that activation of HRR contributes to BCR/ABL-dependent protection from 'spontaneous' as well as drug-induced DSBs (Slupianek et al., 2001 Nowicki et al., 2004) . Enhanced HRR in BCR/ABL-transformed cells may require helicase activity to unwind DNA and generate ssDNA branches to initiate the reaction and/or to resolve potentially toxic recombination intermediates (Fabre et al., 2002) . Indeed, we show that BCR/ABL elevates BLM; this effect may be, at least in part, dependent on BCR/ABLmediated stimulation of cell cycle progression (Cortez et al., 1997; Dutertre et al., 2000) and inhibition of caspase-3 activation (Amarante-Mendes et al., 1998; Bischof et al., 2001; Freire et al., 2001) . BCR/ABLmediated elevation of BLM expression was also observed by another group (Dr Ali Turhan, Institute Gustave Roussy, Villejuif, France, personal communication). However, in contrast to previously described upregulation of RAD51 (Slupianek et al., 2001) , elevation of BLM was not dependent on activation of STAT5 because expression of a constitutively active mutant of STAT5 in 32D parental cells did not modulate the levels of BLM (data not shown). Since We show here that BLM present in BCR/ABLpositive cells is able to exert its helicase activity, and plays a role in BCR/ABL-induced HRR and resistance to genotoxic stress caused by cisplatin (this work) and mitomycin C (data not shown). In addition to BLM, we also show that other RecQ-like helicases can be stimulated by BCR/ABL. They may collaborate with BLM to protect leukemia cells from genotoxic effect of cisplatin. For example, WRN, which seems to play a role in protection against DNA crosslinking agents including cisplatin (Poot et al., 2001) , can interact physically and functionally with BLM (von Kobbe et al., 2002) . The potential role, if any, of other RecQ-like helicases in drug resistance has to be yet determined.
Cisplatin induces a variety of DNA lesions such as intra-and interstrand crosslinks and DNA-protein crosslinks (Sip et al., 1992) . These lesions may be recognized and repaired by nucleotide excision repair (NER) or mismatch repair machinery, or they may lead to DSBs at replication forks (Zdraveski et al., 2000) . RAD51 may allow replication to reinitiate the following replication fork collapse. The resulting HJ would then need to be removed. BLM may be recruited to perform Pull-down assays were performed with the use of GST-BLM(1-212) (a) or GST-RAD51 (b) fusion proteins and total cell lysates from 32D cells and 32D-BCR/ABL (32D-B/A) cells treated with 1 mg/ml cisplatin for 12 h in the absence of IL-3. The amount of RAD51 and BLM in 0.1 of the total cell lysate used for reaction (Input, 10%), of washout (Output, 10%) and in total eluate from the beads (Eluted) was determined by Western analysis. GST-BLM(1-212) and GST-RAD51 were detected in the eluate by Western analysis using anti-GST antibody. (c and d) Immunoprecipitates (IP) of RAD51 (c) or BLM (d) were obtained (IP) from the total cell lysates of 32D cells and 32D-B/A cells treated with 1 mg/ml cisplatin for 12 h in the absence of IL-3. BLM and RAD51 were detected by Western analysis in 0.1 of the total cell lysate used for reaction (Input, 10%), of washout (Output, 10%) and in total eluate from the beads (Eluted). The amount of immunoprecipitated RAD51 (IP:RAD51) or BLM (IP:BLM) was also assessed by Western analysis. (e) Detection of BLM (green), RAD51 (red) and colocalizing (yellow) foci in 32D and 32D-B/A cells untreated (À) and treated with 1 mg/ml of cisplatin for 12 h ( þ ) in the absence of IL-3. Foci formation is presented as the percentage of BLM, RAD51 or BLM þ RAD51 foci surface/DAPI staining surface (at least 50 cells per group were analysed). (f) Nuclear staining of BLM and RAD51 in representative cells. Pictures show nuclear localization of the detected proteins; nuclei borders are outlined in blue this function, which could be achieved by branch migration of the junction toward the end of the chromosome or by resolution of the junction through recruitment of HJ resolvases . BLM helicase interacts with RAD51 in S and G2 cell cycle phases, when HRR primarily occurs ). Immunofluorescence and pull-down assays showed that BCR/ABL facilitates the formation of BLM-RAD51 complexes after DNA damage caused by cisplatin. This phenomenon may simply be associated with elevated expression of BLM and RAD51. However, measurement of DSBs formed in cisplatin-treated BCR/ABLpositive and normal cells by scoring of g-H2AX nuclear foci (Rogakou et al., 1999) revealed that the former cells accumulate more DSBs (data not shown). Thus, numerous BLM-RAD51 foci in BCR/ABL cells may reflect more extensive DNA damage. In addition, we cannot exclude the possibility that BCR/ABL can modify BLM, RAD51 or other proteins to facilitate nuclear localization and/or foci formation by BLM and RAD51.
We hypothesize that efficient BLM foci formation and colocalization with RAD51 in BCR/ABL cells treated with cisplatin is essential for resolving toxic recombination intermediates (Fabre et al., 2002) , thus reducing proapoptotic signaling. This hypothesis is further supported by the finding from Xenopus egg experimental model that absence of BLM leads to the accumulation of chromosomal DNA breaks during S phase (Li et al., 2004) . Elevated frequency of sister chromatid exchange (SCE) associated with loss of BLM in Bloom syndrome patient cells (Bartram et al., 1976) suggested that BLM may inhibit HRR. However, since HRR may result in either SCE or gene conversion (Helleday, 2003) , SCE frequency does not reflect the overall HRR activity.
Cisplatin also causes DNA adducts, which can be repaired by NER (Rosell et al., 2003) . BCR/ABL stimulates NER in myeloid cells (Canitrot et al., 2003; Laurent et al., 2003) ; thus, it is conceivable that HRR and NER collaborate to protect myeloid leukemias from genotoxic effect of cisplatin. Moreover, BLM is also required to facilitate unwinding of DNA near the DSBs for the alignment of microhomology elements used by the nonhomologous end-joining repair pathway (Langland et al., 2002) .
In conclusion, BLM may play an important role in the regulation of the response to genotoxic treatment in BCR/ABL leukemias. Other FTKs such as TEL/ABL, TEL/PDGFbR, TEL/JAK2 and NPM/ALK also enhance the expression of BLM, suggesting a more general role for BLM in the responses of leukemias and lymphomas to DNA damage.
Materials and methods
DNA constructs
pSRa-p210BCR/ABL and pMIG1-p210BCR/ABL-IRES-GFP retroviral constructs were obtained from Dr Charles Sawyers (UCLA, Los Angeles, CA) and Dr Warren Pear (University of Pennsylvania, Philadelphia, PA, USA). Human BLM cDNA was obtained from Dr Ian Hickson (University of Oxford, Oxford, UK) . The BLM fragment (1341-2306 bp) was cloned in the S and AS orientation into pMSCV-neo (Clontech, Palo Alto, CA, USA) or pMIG1-IRES-GFP retroviral construct (gift of Dr Warren Pear). A pEGFPC1 construct containing a nucleus-targeted GFP/BLMD133-237 dominant-negative mutant was obtained from Dr Nathan Ellis (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) (Wang et al., 2001) . pGEX-4T1 encoding GST-BLM(1-212 aa) fusion protein was obtained from Dr Ian Hickson . pGEX-4T2 encoding GST-RAD51 fusion protein was generated in our lab. Cells p210BCR/ABL-positive and RAD51-overexpressing cell lines have been described previously (Sirard et al., 1994; Slupianek et al., 2001 Slupianek et al., , 2002 . 32D and 32D-RAD51 cell lines (Slupianek et al., 2001) were electroporated with pcDNA-BLM-Neo or pcDNA-Neo constructs, and mixtures of clones overexpressing BLM protein were identified by Western analysis after selection in neomycin. Retroviral infections were performed as described (Slupianek et al., 2001) . Draa-BCR/ABL cells were infected with GFP/BLMD133-237 or with GFP retroviral particles (control). 32D-BCR/ABL cells were infected with pMIG1-IRES-GFP retroviral particles containing a fragment of BLM in the S or AS orientation, or with control construct containing GFP only. GFP-positive cells were obtained by sorting. Bone marrow cells (BMCs) from Blm Cin/ þ and Blm þ / þ mice (Goss et al., 2002) were infected with BCR/ ABL-IRES-GFP or IRES-GFP retroviral particles as described . GFP-positive cells were sorted and used for experiments. BMCs from patients with CML in chronic phase (CML-CP), or blast crisis (CML-BC) and from healthy volunteers were collected as described previously . Hematopoietic cell lines (except HL60 and K562) were maintained in the presence of IL-3 or GM-CSF, and primary hematopoietic cells were supplemented with recombinant human IL-3 and stem cell factor (SCF) as described (Skorski et al., 1995) . Growth factors were supplemented, when indicated, in the optimal concentrations necessary to maintain cell proliferation. Draa and Draa-BCR/ABL cells were cultured in a-MEM supplemented with 10% FBS.
Microarray analysis
The sample preparation and array protocol have been published previously .
Northern analysis
Total RNA (10 mg) was isolated and analysed for the expression of BLM mRNA using full-length human BLM cDNA end labeled with [a- 
Inhibitors
The ABL kinase inhibitor STI571 (imatinib mesylate) was obtained from Novartis Pharma AG (Switzerland). The caspases inhibitor Z-VAD-FMK was purchased from Bachem AG (Switzerland).
Immunoprecipitation, GST pull down and Western analysis
GST fusion proteins were expressed and purified as described previously (Klejman et al., 2002) . Cytoplasmic and nuclear cell lysates were obtained as described (Wu et al., 2003) . Immunoprecipitations and pull-downs were carried out as described previously (Slupianek et al., 2001; Trojanek et al., 2003) . Proteins were resolved on SDS-PAGE followed by Western analysis using the antibodies specific for: BLM (Novus Biologicals, Littleton, CO, USA), RAD51 (Upstate USA, Charlottesville, VA, USA), actin, GST and lamin B (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), and tubulin (Calbiochem, San Diego, CA, USA).
Helicase assay
BLM was immunoprecipitated from 32D parental cells and clones expressing BCR/ABL kinase, and used for helicase assays (Dutertre et al., 2002) with the synthetic four-way junction DNA substrate (Mohaghegh et al., 2001) . 
Drug resistance assays
Homologous recombination repair
Draa recombination reporter cells (Pierce et al., 1999) expressing or not p210BCR/ABL kinase were cotransfected with I-SceI expression vector (to induce a DNA DSB in the DR-GFP reporter cassette) and BLM AS cDNA (BLM(AS)), or empty pMSCV-neo plasmid. HRR of GFP allele was evaluated after 48 h by flow cytometry (Slupianek et al., 2001) .
Immunofluorescence
The following primary antibodies recognizing BLM (Novus) or RAD51 (Upstate) and appropriate secondary antibodies conjugated with FITC or TRITC were applied (Molecular Probes Inc., Eugene, OR, USA). DNA was counterstained with the DNA fluorochrome 4 0 ,6 0 diamedino-2-phenylindole (DAPI). Staining and images were processed as described previously (Canitrot et al., 2003) . Only the foci colocalizing with DAPI are included in the calculations.
